Total Payments
$419,802
2024 Payments
$39,542
Companies
13
Transactions
463
Medicare Patients
7,051
Medicare Billing
$260,494
Payment Breakdown by Category
Other$381,753 (90.9%)
Travel$18,342 (4.4%)
Consulting$10,626 (2.5%)
Food & Beverage$8,820 (2.1%)
Education$261.23 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $381,753 | 170 | 90.9% |
| Travel and Lodging | $18,342 | 148 | 4.4% |
| Consulting Fee | $10,626 | 9 | 2.5% |
| Food and Beverage | $8,820 | 128 | 2.1% |
| Education | $261.23 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $130,353 | 158 | $0 (2024) |
| PFIZER INC. | $107,355 | 81 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $95,375 | 100 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $58,278 | 68 | $0 (2024) |
| Lilly USA, LLC | $27,757 | 39 | $0 (2024) |
| Edwards Lifesciences Corporation | $157.88 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $149.98 | 2 | $0 (2018) |
| Novo Nordisk Inc | $131.46 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $85.94 | 6 | $0 (2018) |
| Actelion Pharmaceuticals US, Inc. | $84.99 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,542 | 42 | AstraZeneca Pharmaceuticals LP ($27,054) |
| 2023 | $18,466 | 26 | PFIZER INC. ($10,110) |
| 2022 | $40,640 | 39 | PFIZER INC. ($30,873) |
| 2021 | $42,900 | 28 | PFIZER INC. ($32,825) |
| 2020 | $45,466 | 48 | AstraZeneca Pharmaceuticals LP ($21,656) |
| 2019 | $65,447 | 84 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,110) |
| 2018 | $69,596 | 77 | Boehringer Ingelheim Pharmaceuticals, Inc. ($36,102) |
| 2017 | $97,745 | 119 | Novartis Pharmaceuticals Corporation ($54,585) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $495.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $486.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $168.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $30.53 | General |
| Category: Obesity | ||||||
| 10/20/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/03/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $123.71 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $68.34 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Obesity | ||||||
| 06/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: DIABETES | ||||||
| 06/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $33.50 | General |
| Category: DIABETES | ||||||
| 05/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $101.83 | General |
| Category: DIABETES | ||||||
| 04/11/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $467.66 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $236.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/09/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $38.46 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $569.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $191.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/07/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $83.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/06/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $167.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/05/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/05/2024 | PFIZER INC. | VYNDAQEL (Drug) | Travel and Lodging | In-kind items and services | $129.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/05/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $114.38 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,946 | 2,228 | $407,146 | $66,026 |
| 2022 | 17 | 1,568 | 1,862 | $310,647 | $58,881 |
| 2021 | 19 | 1,678 | 1,962 | $332,169 | $64,198 |
| 2020 | 18 | 1,859 | 2,104 | $369,142 | $71,388 |
Total Patients
7,051
Total Services
8,156
Medicare Billing
$260,494
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 272 | $45,811 | $17,686 | 38.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 340 | 344 | $131,491 | $17,539 | 13.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 89 | 90 | $12,492 | $5,043 | 40.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 89 | 90 | $34,230 | $4,644 | 13.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 45 | 47 | $20,997 | $4,562 | 21.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 476 | 636 | $41,754 | $3,796 | 9.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $5,661 | $2,406 | 42.5% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 179 | 184 | $28,758 | $1,541 | 5.4% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 16 | 16 | $8,505 | $1,317 | 15.5% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 57 | 62 | $8,340 | $1,189 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 26 | $2,944 | $1,109 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $2,070 | $1,046 | 50.5% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 98 | 99 | $36,390 | $989.10 | 2.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $3,213 | $907.80 | 28.3% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 74 | 74 | $9,933 | $659.38 | 6.6% |
| 93793 | Anticoagulant management of patient taking warfarin | Facility | 2023 | 20 | 56 | $2,856 | $496.16 | 17.4% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 67 | 75 | $1,919 | $407.82 | 21.3% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 18 | 19 | $2,016 | $326.70 | 16.2% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 51 | 54 | $3,366 | $130.97 | 3.9% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 14 | 14 | $3,282 | $128.80 | 3.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 15 | 17 | $1,118 | $100.15 | 9.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 289 | $36,540 | $18,836 | 51.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 238 | 243 | $89,216 | $12,378 | 13.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 504 | 689 | $43,776 | $4,160 | 9.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 52 | $15,348 | $4,070 | 26.5% |
About Dr. David Grambow, MD
Dr. David Grambow, MD is a Cardiovascular Disease healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235178674.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Grambow, MD has received a total of $419,802 in payments from pharmaceutical and medical device companies, with $39,542 received in 2024. These payments were reported across 463 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($381,753).
As a Medicare-enrolled provider, Grambow has provided services to 7,051 Medicare beneficiaries, totaling 8,156 services with total Medicare billing of $260,494. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Milwaukee, WI
- Active Since 06/04/2006
- Last Updated 06/12/2012
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1235178674
Products in Payments
- JARDIANCE (Drug) $144,507
- VYNDAQEL (Drug) $107,334
- ENTRESTO (Drug) $95,375
- FARXIGA (Drug) $29,947
- WAINUA (Drug) $28,325
- PRADAXA (Drug) $13,596
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $157.88
- XARELTO (Drug) $85.94
- OPSUMIT (Drug) $84.99
- Wegovy (Drug) $52.51
- BYSTOLIC (Drug) $29.28
- Resolute (Device) $27.44
- ELIQUIS (Drug) $17.92
- BRILINTA (Drug) $5.13
- VYNDAMAX (Drug) $2.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Milwaukee
Jodi Zilinski, M.d, M.D
Cardiovascular Disease — Payments: $129,860
Cardiovascular Disease $129,860
Saif Anwaruddin, Md, MD
Cardiovascular Disease — Payments: $125,093
Cardiovascular Disease $125,093
Iftikhar Kullo, M.d, M.D
Cardiovascular Disease — Payments: $71,275
Cardiovascular Disease $71,275
Evgenia Raichlin, Md, MD
Cardiovascular Disease — Payments: $68,892
Cardiovascular Disease $68,892
Jasbir Sra, Md, MD
Cardiovascular Disease — Payments: $51,093
Cardiovascular Disease $51,093
Christian Breburda, Md, MD
Cardiovascular Disease — Payments: $37,597
Cardiovascular Disease $37,597